With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Misfolded alpha-synuclein (αSyn) aggregates are a hallmark event in Parkinson's disease
(PD) and other synucleinopathies. Recently, αSyn seed amplification assays (αSyn-SAAs) …

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for
Parkinson's disease (PD) and related synucleinopathies. They enable detection of seeding …

A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

Background Misfolded α‐synuclein (αSyn) aggregates (αSyn‐seeds) in cerebrospinal fluid
(CSF) are biomarkers for synucleinopathies such as Parkinson's disease (PD). αSyn‐seeds …

Objective The purpose of this study was to determine the sensitivity and specificity of α‐
synuclein seed amplification assay (αSyn‐SAA) in antemortem and postmortem …

Background Aggregation of α-synuclein (α-syn) is a prominent feature of Parkinson's
disease (PD) and other synucleinopathies. Currently, α-syn seed amplification assays …

Synucleinopathies are a group of neurodegenerative diseases (NDs) associated with
cerebral accumulation of α-synuclein (αSyn) misfolded aggregates. At this time, there is no …